Immunoglobulin heavy variable 4-34 (IGHV4-34) B-cell receptor idiotype (IGHV4-34 BCR idiotype)

The Immunoglobulin heavy variable 4-34 (IGHV4-34) B-cell receptor idiotype is a specific antigenic structure on the variable region of B-cell receptors (BCRs) encoded by the IGHV4-34 germline gene (Pugh-Bernard et al., 2001, J Clin Invest). This gene is distinguished by its intrinsic autoreactivity, particularly its ability to bind I/i carbohydrate antigens on erythrocytes, which is the primary cause of cold agglutinin disease (Berentsen et al., 2006, Br J Haematol). In healthy individuals, IGHV4-34-expressing B-cells are typically censored or maintained in a state of anergy, but they frequently expand in autoimmune conditions like systemic lupus erythematosus (SLE) and various B-cell malignancies (Isenberg et al., 1993, J Autoimmun). In chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL), the use of the IGHV4-34 gene is associated with specific clinical outcomes and may drive lymphomagenesis through autonomous BCR signaling (Ghia et al., 2005, Blood). Therapeutic strategies targeting this idiotype, such as the 9G4 monoclonal antibody, aim to selectively deplete pathogenic B-cell clones while sparing the rest of the B-cell repertoire (Kobatake et al., 2020, Cancer Sci). This approach offers a highly specific alternative to broad B-cell depletion therapies, potentially reducing the risk of global immunosuppression. The idiotype serves as both a therapeutic target and a diagnostic biomarker for identifying specific subsets of B-cell disorders. Research into this target continues to explore its role in the development of targeted immunotherapies for refractory autoimmune and oncological diseases.

Other names

VH4-34V4-349G4 idiotypeIGHV4-34 gene product

Targeted depletion of B-cells expressing the IGHV4-34 idiotype via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and neutralization of autoreactive B-cell receptor signaling.